Skip to Main Content

Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made it this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Hope you conquer the world and, as always, do keep in touch …

AstraZeneca (AZN) received a boost for its oncology business thanks to results of a clinical trial showing its Lynparza drug helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment, Reuters reports. The result should generate expanded use of the medicine, which is being developed and marketed with Merck (MRK) under a deal struck last year. Analysts say first-line use could boost sales by more than $1 billion a year, although doctors will first want to see the scale of the clinical benefit when full results are presented at a medical meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!